FY2025 Earnings Forecast for FBIO Issued By HC Wainwright

Fortress Biotech, Inc. (NASDAQ:FBIO) – Equities researchers at HC Wainwright issued their FY2025 earnings estimates for shares of Fortress Biotech in a research note issued on Tuesday, January 13th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.20) per share for the year. The consensus estimate for Fortress Biotech’s current full-year earnings is ($3.28) per share. HC Wainwright also issued estimates for Fortress Biotech’s Q4 2025 earnings at $0.42 EPS, FY2026 earnings at $0.62 EPS and FY2027 earnings at $1.51 EPS.

FBIO has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Fortress Biotech in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Fortress Biotech from a “hold” rating to a “buy” rating in a report on Sunday, November 23rd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $16.50.

Fortress Biotech Trading Down 15.9%

FBIO opened at $3.28 on Thursday. The company has a quick ratio of 1.97, a current ratio of 2.19 and a debt-to-equity ratio of 0.73. The stock’s fifty day moving average is $3.19 and its two-hundred day moving average is $2.78. The company has a market capitalization of $101.81 million, a P/E ratio of -18.22 and a beta of 1.42. Fortress Biotech has a 52 week low of $1.33 and a 52 week high of $4.53.

Fortress Biotech (NASDAQ:FBIO) last announced its quarterly earnings results on Friday, November 14th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.54. Fortress Biotech had a negative return on equity of 69.39% and a net margin of 6.40%.The firm had revenue of $17.63 million during the quarter, compared to analyst estimates of $21.02 million.

Institutional Investors Weigh In On Fortress Biotech

A number of hedge funds have recently made changes to their positions in the stock. HB Wealth Management LLC purchased a new position in Fortress Biotech in the third quarter valued at about $444,000. Vanguard Group Inc. lifted its position in shares of Fortress Biotech by 11.4% during the third quarter. Vanguard Group Inc. now owns 950,327 shares of the biopharmaceutical company’s stock valued at $3,511,000 after buying an additional 97,405 shares during the last quarter. Sheets Smith Investment Management bought a new stake in shares of Fortress Biotech in the 3rd quarter valued at about $270,000. Panagora Asset Management Inc. purchased a new position in shares of Fortress Biotech in the 2nd quarter worth approximately $93,000. Finally, Shikiar Asset Management Inc. grew its position in shares of Fortress Biotech by 18.0% in the 2nd quarter. Shikiar Asset Management Inc. now owns 278,469 shares of the biopharmaceutical company’s stock worth $518,000 after buying an additional 42,500 shares during the last quarter. 96.51% of the stock is currently owned by hedge funds and other institutional investors.

About Fortress Biotech

Fortress Biotech, Inc is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.

Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies.